-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Short Interest in Helius Medical Technologies, Inc. (NASDAQ:HSDT) Rises By 192.7%
Short Interest in Helius Medical Technologies, Inc. (NASDAQ:HSDT) Rises By 192.7%
Helius Medical Technologies, Inc. (NASDAQ:HSDT – Get Rating) was the recipient of a large growth in short interest in the month of July. As of July 31st, there was short interest totalling 173,600 shares, a growth of 192.7% from the July 15th total of 59,300 shares. Based on an average daily trading volume, of 2,350,000 shares, the short-interest ratio is presently 0.1 days.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of HSDT. Altium Capital Management LP bought a new position in shares of Helius Medical Technologies in the fourth quarter worth $254,000. Kepos Capital LP boosted its stake in Helius Medical Technologies by 296.4% in the fourth quarter. Kepos Capital LP now owns 100,304 shares of the company's stock valued at $521,000 after buying an additional 75,000 shares in the last quarter. Finally, AIGH Capital Management LLC acquired a new stake in Helius Medical Technologies in the fourth quarter valued at about $1,298,000. Institutional investors own 29.74% of the company's stock.
Get Helius Medical Technologies alerts:Helius Medical Technologies Stock Performance
Shares of NASDAQ HSDT opened at $0.51 on Thursday. Helius Medical Technologies has a 52 week low of $0.45 and a 52 week high of $15.68. The stock has a market capitalization of $1.94 million, a P/E ratio of -0.07 and a beta of 0.72. The stock's fifty day moving average is $1.33 and its 200 day moving average is $2.52.
Helius Medical Technologies (NASDAQ:HSDT – Get Rating) last issued its quarterly earnings results on Thursday, May 12th. The company reported ($1.15) EPS for the quarter. Helius Medical Technologies had a negative return on equity of 240.53% and a negative net margin of 3,043.95%. The company had revenue of $0.19 million during the quarter. During the same quarter in the prior year, the firm earned ($1.65) EPS. Equities research analysts forecast that Helius Medical Technologies will post -4.18 earnings per share for the current year.About Helius Medical Technologies
(Get Rating)
Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.
Recommended Stories
- Get a free copy of the StockNews.com research report on Helius Medical Technologies (HSDT)
- Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
- The 2 Dow Stocks with Decade-Long Win Streaks on the Line
- Could Rite Aid Be an Acquisition Target, Again?
- The How And Why of Investing in Oil Stocks
- The How and Why of Investing in Gold Stocks
Receive News & Ratings for Helius Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
Helius Medical Technologies, Inc. (NASDAQ:HSDT – Get Rating) was the recipient of a large growth in short interest in the month of July. As of July 31st, there was short interest totalling 173,600 shares, a growth of 192.7% from the July 15th total of 59,300 shares. Based on an average daily trading volume, of 2,350,000 shares, the short-interest ratio is presently 0.1 days.
和力士医疗技术公司(纳斯达克:HSDT-GET评级)是7月份空头股数大幅增长的接受者。截至7月31日,空头股数共有173,600股,比7月15日的59,300股增长了192.7%。以日均成交量2,350,000股计算,目前短息比为0.1天。
Institutional Inflows and Outflows
机构资金流入和流出
A number of hedge funds have recently modified their holdings of HSDT. Altium Capital Management LP bought a new position in shares of Helius Medical Technologies in the fourth quarter worth $254,000. Kepos Capital LP boosted its stake in Helius Medical Technologies by 296.4% in the fourth quarter. Kepos Capital LP now owns 100,304 shares of the company's stock valued at $521,000 after buying an additional 75,000 shares in the last quarter. Finally, AIGH Capital Management LLC acquired a new stake in Helius Medical Technologies in the fourth quarter valued at about $1,298,000. Institutional investors own 29.74% of the company's stock.
多家对冲基金最近调整了对HSDT的持股。Altium Capital Management LP在第四季度购买了Helius Medical Technologies价值25.4万美元的新头寸。Kepos Capital LP在第四季度将其在Helius Medical Technologies的持股增加了296.4%。Kepos Capital LP现在拥有100,304股该公司股票,价值521,000美元,上个季度又购买了75,000股。最后,AIGH Capital Management LLC在第四季度收购了Helius Medical Technologies的新股份,价值约1,298,000美元。机构投资者持有该公司29.74%的股票。
Helius Medical Technologies Stock Performance
Helius医疗技术公司股票表现
Shares of NASDAQ HSDT opened at $0.51 on Thursday. Helius Medical Technologies has a 52 week low of $0.45 and a 52 week high of $15.68. The stock has a market capitalization of $1.94 million, a P/E ratio of -0.07 and a beta of 0.72. The stock's fifty day moving average is $1.33 and its 200 day moving average is $2.52.
周四,新浪纳斯达克的股价开盘报0.51美元。Helius Medical Technologies的52周低点为0.45美元,52周高点为15.68美元。该股市值为194万美元,市盈率为-0.07,贝塔系数为0.72。该股的50日移动均线切入位为1.33美元,200日移动均线切入位为2.52美元。
About Helius Medical Technologies
关于Helius医疗技术公司
(Get Rating)
(获取评级)
Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.
Helius医疗技术公司是一家神经技术公司,专注于开发、许可和获取非侵入性技术,用于治疗神经疾病或创伤引起的症状。其产品便携式神经调节刺激器(PONS)是一种非手术医疗设备,旨在用于短期治疗因多发性硬化症症状而导致的步态缺陷和因轻至中度创伤性脑损伤而导致的平衡障碍,以及与有监督的治疗锻炼一起使用。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Helius Medical Technologies (HSDT)
- Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
- The 2 Dow Stocks with Decade-Long Win Streaks on the Line
- Could Rite Aid Be an Acquisition Target, Again?
- The How And Why of Investing in Oil Stocks
- The How and Why of Investing in Gold Stocks
- 免费获取StockNews.com关于Helius医疗技术(HSDT)的研究报告
- 大型和小型石油和天然气类股盈利后反弹
- 连续十年上涨的两只道指股票
- Rite Aid会再次成为收购目标吗?
- 投资石油股票的方式和原因
- 投资黄金股票的方式和原因
Receive News & Ratings for Helius Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
接受《赫利乌斯医疗技术日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Helius医疗技术公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧